Nymox Pharmaceutical Announces Prostate Cancer Clinical Trial Will Complete Prospective 18 Month Post-Treatment Assessments
HASBROUCK HEIGHTS, N.J., Oct. 08, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that that participants in prostate cancer clinical trial NX03-0040 had neared completion of the study's 18 month post-treatment assessments. The results from this 18 month study are expected to be reported this quarter, after the 18 month data has been analyzed. Patients in the prostate cancer study have been followed for up to 39 months after treatment.
Study NX03-0040 is a Phase 2 study of NX-1207 for low grade localized prostate cancer. The study was initiated in 2012. 146 men were randomized to a single injection of NX-1207 at two dosage levels (2.5 mg or 15 mg) or standard of care. Prostate cancer is the most commonly diagnosed cancer in men, other than skin cancer, and is the second leading cause of cancer death for men. Approximately 50% of prostate cancers are initially considered low risk.
To date, NX-1207 has had an excellent safety profile. NX-1207 has shown safety in 9 clinical trials (BPH and prostate cancer) including repeat injection studies. The drug does not lead to immune responses such as antibody formation which can cause significant drug toxicity and/or limit usage to single treatments due to drug neutralizing effects.
One of the major problems with current prostate treatments for localized prostate cancer (radical prostatectomy, external beam radiation, or brachytherapy) is the relatively high incidence of reported sexual dysfunction post-treatment. In 9 studies, NX-1207 treatment has been shown to have no significant adverse effect post-treatment on sexual function or testosterone levels.
For more information please contact info@nymox.com or 800-936-9669.
Help employers find you! Check out all the jobs and post your resume.
Study NX03-0040 is a Phase 2 study of NX-1207 for low grade localized prostate cancer. The study was initiated in 2012. 146 men were randomized to a single injection of NX-1207 at two dosage levels (2.5 mg or 15 mg) or standard of care. Prostate cancer is the most commonly diagnosed cancer in men, other than skin cancer, and is the second leading cause of cancer death for men. Approximately 50% of prostate cancers are initially considered low risk.
To date, NX-1207 has had an excellent safety profile. NX-1207 has shown safety in 9 clinical trials (BPH and prostate cancer) including repeat injection studies. The drug does not lead to immune responses such as antibody formation which can cause significant drug toxicity and/or limit usage to single treatments due to drug neutralizing effects.
One of the major problems with current prostate treatments for localized prostate cancer (radical prostatectomy, external beam radiation, or brachytherapy) is the relatively high incidence of reported sexual dysfunction post-treatment. In 9 studies, NX-1207 treatment has been shown to have no significant adverse effect post-treatment on sexual function or testosterone levels.
For more information please contact info@nymox.com or 800-936-9669.
Help employers find you! Check out all the jobs and post your resume.